Clopidogrel resistance: What's new?

Archives of Cardiovascular Diseases

Volumn 103, Issue 6-7, 2010, Pages 349-353

  Cuisset, Thomas ^a   Cayla, Guillaume ^b   Silvain, Johanne ^c  

^a TIMONE HOSPITAL   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; Clopidogrel resistance; Genetic polymorphisms; Platelet function tests

Indexed keywords

CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; DRUG DOSE INCREASE; DRUG RESPONSE; GENETIC POLYMORPHISM; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; REVIEW;

EID: 77956712459     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2010.05.001     Document Type: Article

References (34)

1. J.S. Hulot, A. Bura, and E. Villard Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
2. D. Sibbing, W. Koch, and D. Gebhard Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
3. S. Bhattacharyya, and R. Rakhit Cytochrome P450 2C19 polymorphism and clopidogrel after MI Lancet 373 2009 1171 author reply 72-3
4. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy Jama 302 2009 849 857
5. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
6. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
7. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
8. T. Cuisset, C. Frere, and J. Quilici Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study J Am Coll Cardiol 54 2009 1149 1153
9. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
10. D.J. Angiolillo, E. Bernardo, and M. Sabate Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547
11. J.P. Collet, J. Silvain, and A. Landivier Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelet therapy (RELOAD) study Circulation 118 2008 1225 1233
12. T. Cuisset, C. Frere, and R. Poyet Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non-responder patients after coronary stenting Arch Cardiovasc Dis 103 2010 39 45
13. N. von Beckerath, G. Pogatsa-Murray, and A. Wieczorek Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness Thromb Haemost 95 2006 910 911
14. P. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317
15. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
16. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
17. W.M. Samara, K.P. Bliden, and U.S. Tantry The difference between clopidogrel responsiveness and posttreatment platelet reactivity Thromb Res 115 2005 89 94
18. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation Jama 303 2010 754 762
19. G. Cayla, J.C. Macia, and H. Rabesandratana Flow cytometric assessment of vasodilator-stimulated phosphoprotein: prognostic value of recurrent cardiovascular events after acute coronary syndromes Arch Cardiovasc Dis 101 2008 743 751
20. A. Bellemain-Appaix, G. Montalescot, and J. Silvain Slow response to clopidogrel predicts low response J Am Coll Cardiol 55 2010 815 822
21. T. Cuisset, G. Cayla, and C. Frere Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5 2009 325 329
22. G. Montalescot, G. Sideris, and C. Meuleman A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial J Am Coll Cardiol 48 2006 931 938
23. S.R. Mehta, J.P. Bassand, and S. Chrolavicius Design and rationale of CURRENT-OASIS7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy Am Heart J 156 2008 1080-88 e1
24. T. Palmerini, C. Barozzi, and L. Tomasi A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study Thromb Res 125 2010 309 314
25. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
26. T. Cuisset, C. Frere, and J. Quilici Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel non-responders: a prospective, randomized study JACC Cardiovasc Interv 1 2008 649 653
27. M. Valgimigli, G. Campo, and N. de Cesare Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study Circulation 119 2009 3215 3222
28. A. Pena, J.P. Collet, and J.S. Hulot Can we override clopidogrel resistance? Circulation 119 2009 2854 2857
29. G. Montalescot, G. Sideris, and R. Cohen Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study Thromb Haemost 103 2010 213 223
30. S.D. Wiviott, D. Trenk, and A.L. Frelinger Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial Circulation 116 2007 2923 2932
31. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
32. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
33. G. Montalescot, S.D. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
34. S.D. Wiviott, E. Braunwald, and D.J. Angiolillo Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Circulation 118 2008 1626 1636